Introduction
Anaplastic carcinoma of the pancreas is a rare aggressive pancreatic tumor and accounts for 2-7% of all pancreatic cancers with a male predominance [1, 2] . It is a rare pancreatic tumor of epithelial origin, frequently showing various morphologies which include spindle cell type, pleomorphic cell type and giant cell type. Many terms have been used for this tumor which implies pleomorphic carcinoma, pleomorphic giant cell carcinoma, pleomorphic large cell carcinoma, sarcomatoid carcinoma and undifferentiated carcinoma [1] [2] [3] . According to the guidelines of the World Health Organization (WHO) in 2010, these carcinomas were classified as undifferentiated (anaplastic) carcinomas. We herein present a case of anaplastic carcinoma of the pancreas (ACP) with remarkable intraductal tumor growth into the head of pancreas.
Case Presentation
A 63-year-old male patient was admitted to our hospital due to abdomen and back pain, jaundice and weight loss. Laboratory investigations revealed hemoglobin: 12 g/L, total/direct bilirubin: 2.5/1.9 mg/dl, carcinoembryonic antigen: 8.5 (0-3.4) ng/ml, and carbohydrate antigen (CA) 19-9: 218.7 (<39) U/ml. Transabdominal ultrasonography showed suspected pancreatic mass lesion, and abdominal computed tomography revealed a hypo-echoic mass lesion in the head of the pancreas that accompanied with severe dilatation of the biliary duct. No distant metastasis or lymph node involvement was detected. We performed pancreatoduodenectomy and lymph node dissection.
On macroscopic examination, the tumor was localized in the head of pancreas and measured 5 x 4 x 3.5 cm. On cross section, it was rubbery and fleshy and also revealed hemorrhage and extensive necrosis. The tumor grossly infiltrated into peripancreatic adipose tissue. Histopathologically the tumor, showed, composed of poorly cohesive, pleomorphic mononuclear cells admixed with bizarre multinucleated giant cells that contain abundant eosinophilic cytoplasm, and scant stroma (Figure 1 ). 
Cytokeratin 7 (x4); (B) Vimentin (x10); (C) CD 68 (x10) and (D) epithelial membrane antigen (EMA) (x10).
The final pathological diagnosis was anaplastic carcinoma of the pancreas.
The postoperative course was uneventful and the patient discharged from hospital without complication after surgery. The patient died four months after surgery due to systemic adverse effect of the disease.
Discussion
Anaplastic carcinoma of the pancreas is a very rare histologic subtype of pancreatic cancer and associated with more aggressive tumor and poor prognosis behavior than pancreatic ductal adenocarcinoma. Also, it is frequently diagnosed at an advanced stage with a cystic bulky tumor and adjacent organ involvement. The incidence of anaplastic carcinoma changes between 2.1% and 6.8% among reported case series [4, 5] . It was first reported by Sommers and Meissner as pleomorphic carcinoma. Patients usually have huge tumors showing rapid growth when detected and associated with a very poor prognosis [6] . It is usually seen as a large cystic pancreatic tumor with areas of hemorrhage and necrosis. In our case, the tumor was rubbery and fleshy that revealed hemorrhage and extensive necrosis and grossly infiltrated into peripancreatic adipose tissue. The clinical features caused by this rare tumor are abdominal pain, fatigue, jaundice, body weight loss, anorexia and back pain, which remind symptoms of adenocarcinoma. Hoshimoto, et al. stated that anaplastic carcinoma should be considered when diagnosing pancreatic tumors with a cyst-like appearance, especially in the presence of severe anemia, elevated leucocyte counts, or elevated serum CA 19-9 levels [7] . In our case, laboratory examinations revealed anemia and marked elevated CA 19-9 level (218 U/mL).
ACP is associated with poorer survival when compared to invasive ductal adenocarcinomas. Neither curative resection nor chemotherapy or radiotherapy has been shown to have any benefit due to the aggressive nature and rapid recurrence rates of the disease [8] . Palliative care and close monitoring are the only therapeutic options in most of the cases. Treatment alternatives for this dismal disease remain to be defined.
